NasdaqGM - Delayed Quote USD

TriSalus Life Sciences, Inc. (TLSIW)

1.4000

+0.0200

+(1.45%)

As of May 15 at 4:00:00 PM EDT. Market Open.

TriSalus Life Sciences Inc (TLSI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...

TriSalus Life Sciences Inc (TLSI) reports a 42% increase in net sales and significant milestones, despite facing operating losses and strategic challenges.

GuruFocus.com 35 minutes ago

TLSI

TLSIW
+1.45%
TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance

DENVER, May 15, 2025--TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance

Business Wire yesterday

TLSI

TLSIW
+1.45%
TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call

DENVER, May 12, 2025--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, announced today that it will host a conference call and webcast on Thursday May 15, 2025 at 8:00 AM eastern time to discuss its financial results for the quarter ended March 31, 2025. A press release detailing the results wil

Business Wire 3 days ago

TLSI

TLSIW
+1.45%
TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results

DENVER, April 30, 2025--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications, today announces preliminary financial results for Q1 202

Business Wire 16 days ago

TLSI

TLSIW
+1.45%
TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

DENVER, March 27, 2025--TriSalus Life Sciences Inc., (Nasdaq: TLSI), oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications, today announced its financial results for the fourth quarter and full year

Business Wire last month

TLSI

TLSIW
+1.45%
TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping

DENVER, March 26, 2025--TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that the Centers for Medicare & Medicaid Services (CMS) has established a new Level II HCPCS code for the TriNav® Infusion System, effective April 1, 2025. This new code, C8004, provides reimburseme

Business Wire last month

TLSI

TLSIW
+1.45%
TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of "Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model"

DENVER, March 06, 2025--TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), TriSalus Life Sciences, which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that company researchers received two JVIR Top Paper Awards for a recent publication, including the JVIR Editor’s Award for Distinguished Laboratory Investigation and the JVI

Business Wire 2 months ago

TLSI

TLSIW
+1.45%
TriSalus Life Sciences Announces Key Appointments to Board of Directors

DENVER, February 03, 2025--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its investigational immunotherapy, today announced the appointment of two distinguished HealthCare Industry veterans to its Board of Directors. Mr. William J. Valle and Gary B. Gordon, M.D., Ph.D., joined the Company’s Board of Directors, effective

Business Wire 3 months ago

TLSI

TLSIW
+1.45%
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed

DENVER, February 03, 2025--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its investigational immunotherapy, today announced that it has requested a drawdown of $10 million under its previously announced $50 million credit agreement with OrbiMed, a healthcare investment firm.

Business Wire 3 months ago

TLSI

TLSIW
+1.45%
TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call

DENVER, January 23, 2025--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), is announcing preliminary unaudited fourth quarter and full year 2024 financial results and details of the upcoming conference call.

Business Wire 3 months ago

TLSI

TLSIW
+1.45%
TriSalus Life Sciences announces publication of pre-clinical data

TriSalus Life Sciences (TLSI) announced the publication of research titled, “Pressure Enabled Drug Delivery Significantly Increases Intraarterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Model,” in the peer-reviewed Journal of Vascular and Interventional Radiology. “This study further validates the potential of TriNav using the PEDD approach to transform the treatment of liver tumors. By significantly enhancing therapeutic delivery and sparing healthy tissue, PEDD offers a p

TipRanks 4 months ago

TLSI

TLSIW
+1.45%
TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System

DENVER, January 09, 2025--TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), TriSalus Life Sciences seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today the publication of research titled, "Pressure Enabled Drug Delivery (PEDD) Significantly Increases Intraarterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Mode

Business Wire 4 months ago

TLSI

TLSIW
+1.45%
TriSalus Announces Leadership Changes

DENVER, January 08, 2025--TriSalus announces leadership changes.

Business Wire 4 months ago

TLSI

TLSIW
+1.45%
TriSalus Reports Q3 2024 Financial Results and Provides Business Update

DENVER, November 14, 2024--TriSalus Life Sciences Inc., (Nasdaq: TLSI), an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced its financial results for the third quarter ended September 30, 2024, and provided a business update.

Business Wire 5 months ago

TLSI

TLSIW
+1.45%
TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

DENVER, November 11, 2024--TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients suffering from liver cancer through its advanced delivery technology as well as an investigational immunotherapy, nelitolimod, has announced a strategic partnership with Geo-Med, LLC ("Geo-Med"), a certified Service-Disabled Veteran-Owned Small Business (SDVOSB), to expand availability of the TriNav Infusion System ("TriNav") to U.

Business Wire 6 months ago

TLSI

TLSIW
+1.45%
TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

DENVER, November 07, 2024--TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), a leader in oncology innovations integrating advanced delivery technology to transform treatment for liver and pancreatic tumors, today announced the launch of the TriNav® LV Infusion System and TriGuide™ Guiding Catheter. These new devices are designed to optimize therapeutic delivery, enhancing treatment options and potentially improving outcomes for patients.

Business Wire 6 months ago

TLSI

TLSIW
+1.45%
TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

DENVER, October 31, 2024--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, announced today it will host a conference call and webcast on November 14, 2024, at 9:00 a.m. ET to discuss financial results for the third quarter ended September 30, 2024, and provide a business update. A press release detailing the third quarter re

Business Wire 6 months ago

TLSI

TLSIW
+1.45%
TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

DENVER, October 14, 2024--TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, announced today that Mary Szela, Chief Executive Officer and President of TriSalus, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024.

Business Wire 6 months ago

TLSI

TLSIW
+1.45%
TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

DENVER, September 26, 2024--TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, has announced the addition of Riad Salem, M.D., to its Scientific Advisory Board (SAB).

Business Wire 7 months ago

TLSI

TLSIW
+1.45%
TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System

DENVER, September 23, 2024--TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with standard of care therapies and immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the publication of research titled, "Intra-arterial Pressure-Enabled Drug Delivery Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model," in the peer-reviewed Jou

Business Wire 7 months ago

TLSI

TLSIW
+1.45%

Performance Overview

Return	TLSIW	S&P 500 (^GSPC)
YTD	+27.27%	+1.16%
1-Year	+47.37%	+12.32%
3-Year	+600.00%	+48.45%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TriSalus Life Sciences, Inc. (TLSIW)

TriSalus Life Sciences Inc (TLSI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...

TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance

TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call

TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results

TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping

TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of "Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model"

TriSalus Life Sciences Announces Key Appointments to Board of Directors

TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed

TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call

TriSalus Life Sciences announces publication of pre-clinical data

TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System

TriSalus Announces Leadership Changes

TriSalus Reports Q3 2024 Financial Results and Provides Business Update

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System

Performance Overview